<DOC>
	<DOCNO>NCT00073749</DOCNO>
	<brief_summary>To determine Maximum Tolerated Dose ( MTD ) , tolerability , initial safety profile CMC-544 subject B-cell Non-Hodgkin 's Lymphoma ( NHL ) .</brief_summary>
	<brief_title>Study Evaluating CMC-544 In B-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Subjects previously diagnose CD22positive , Bcell NHL , accord WHO classification , progress least 2 prior therapy probable clinical benefit At expanded cohort , part 2 study , subject must one following : Follicular lymphoma previously treat least one dose rituximab , receive radioimmunotherapy Diffuse large Bcell lymphoma Age 18 year old Candidate potentially curative therapy opinion investigator Chronic lymphocytic leukemia Burkitt 's lymphoma , primary effusion lymphoma , precursor Bcell lymphoblastic lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>B-Cell</keyword>
	<keyword>Non-Hodgkin 's</keyword>
	<keyword>Lymphoma</keyword>
</DOC>